Abstract:Reprogramming of cancer metabolism has become increasingly concerned over the last decade, particularly the reprogramming of glucose metabolism, also known as the "Warburg effect". The reprogramming of glucose metabolism is considered a novel hallmark of human cancers. A growing number of studies have shown that reprogramming of glucose metabolism can regulate many biological processes of cancers, including carcinogenesis, progression, metastasis, and drug resistance. In this review, we summarize the major biological functions, clinical significance, potential targets and signaling pathways of glucose metabolic reprogramming in human cancers. Moreover, the applications of natural products and small molecule inhibitors targeting glucose metabolic reprogramming are analyzed, some clinical agents targeting glucose metabolic reprogramming and trial statuses are summarized, as well as the pros and cons of targeting glucose metabolic reprogramming for cancer therapy are analyzed. Overall, the reprogramming of glucose metabolism plays an important role in the prediction, prevention, diagnosis and treatment of human cancers. Glucose metabolic reprogramming-related targets have great potential to serve as biomarkers for improving individual outcomes and prognosis in cancer patients. The clinical innovations related to targeting the reprogramming of glucose metabolism will be a hotspot for cancer therapy research in the future. We suggest that more high-quality clinical trials with more abundant drug formulations and toxicology experiments would be beneficial for the development and clinical application of drugs targeting reprogramming of glucose metabolism.This review will provide the researchers with the broader perspective and comprehensive understanding about the important significance of glucose metabolic reprogramming in human cancers.

Autonomous Glucose Metabolic Reprogramming of Tumour Cells under Hypoxia: Opportunities for Targeted Therapy

Hypoxia Boosts Aerobic Glycolysis in Carcinoma: A Complex Process for Tumour Development

Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism

Analysis of Hypoxia-Induced Metabolic Reprogramming.

HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance

Hypoxia and Cancer Cell Metabolism

Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies

Metabolomic Investigations into Hypoxia-Mediated Metabolic Reprogramming of Pancreatic Cancer Cells

Advances in the Targeting of HIF-1α and Future Therapeutic Strategies for Glioblastoma Multiforme

Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target

How to overcome (and exploit) tumor hypoxia for targeted gene therapy

Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance

Tumor hypoxia: From basic knowledge to therapeutic implications

Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target

HIF-1-Regulated Glucose Metabolism: A Key to Apoptosis Resistance?

Central role of hypoxia-inducible factor-1α in metabolic reprogramming of cancer cells: A review

Role of hypoxia in the tumor microenvironment and targeted therapy

Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells

Reprogramming of glucose metabolism: The hallmark of malignant transformation and target for advanced diagnostics and treatments

Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment